JP2006502112A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006502112A5 JP2006502112A5 JP2004520114A JP2004520114A JP2006502112A5 JP 2006502112 A5 JP2006502112 A5 JP 2006502112A5 JP 2004520114 A JP2004520114 A JP 2004520114A JP 2004520114 A JP2004520114 A JP 2004520114A JP 2006502112 A5 JP2006502112 A5 JP 2006502112A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- substituted
- membered
- alkyl
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 amino, hydroxy Chemical group 0.000 claims 113
- 125000000623 heterocyclic group Chemical group 0.000 claims 47
- 150000001875 compounds Chemical class 0.000 claims 41
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 26
- 125000001424 substituent group Chemical group 0.000 claims 18
- 125000005843 halogen group Chemical group 0.000 claims 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims 7
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 7
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 6
- 101150065749 Churc1 gene Proteins 0.000 claims 6
- 102100038239 Protein Churchill Human genes 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 claims 5
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 4
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 2
- 101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 claims 2
- SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- ZXOFVTMVRJWTAG-UHFFFAOYSA-N n-(1-acetyl-3,3-dimethyl-2h-indol-6-yl)-2-(pyridin-4-ylmethylamino)benzamide Chemical compound C1=C2N(C(=O)C)CC(C)(C)C2=CC=C1NC(=O)C1=CC=CC=C1NCC1=CC=NC=C1 ZXOFVTMVRJWTAG-UHFFFAOYSA-N 0.000 claims 2
- BPPJLUFEJJNKCY-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)benzamide Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CC=C1NCC1=CC=NC=C1 BPPJLUFEJJNKCY-UHFFFAOYSA-N 0.000 claims 2
- FNFSNNWULZMNNC-UHFFFAOYSA-N n-(4,4-dimethyl-2,3-dihydro-1h-isoquinolin-7-yl)-2-[[2-(methylamino)pyrimidin-4-yl]methylamino]benzamide Chemical compound CNC1=NC=CC(CNC=2C(=CC=CC=2)C(=O)NC=2C=C3C(C(CNC3)(C)C)=CC=2)=N1 FNFSNNWULZMNNC-UHFFFAOYSA-N 0.000 claims 2
- HBLHQDSWCAZXOG-UHFFFAOYSA-N n-(4,4-dimethyl-2,3-dihydro-1h-quinolin-7-yl)-2-(quinazolin-6-ylamino)benzamide Chemical compound N1=CN=CC2=CC(NC3=CC=CC=C3C(=O)NC=3C=C4NCCC(C4=CC=3)(C)C)=CC=C21 HBLHQDSWCAZXOG-UHFFFAOYSA-N 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000004942 pyridazin-6-yl group Chemical group N1=NC=CC=C1* 0.000 claims 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 2
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 claims 2
- 125000004547 quinazolin-6-yl group Chemical group N1=CN=CC2=CC(=CC=C12)* 0.000 claims 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 claims 1
- PYWPWPPRAYOLIB-UHFFFAOYSA-N 1-(3,3-dimethyl-2h-indol-1-yl)ethanone Chemical compound C1=CC=C2N(C(=O)C)CC(C)(C)C2=C1 PYWPWPPRAYOLIB-UHFFFAOYSA-N 0.000 claims 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 1
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims 1
- OIPPARMLEWQGSK-UHFFFAOYSA-N 2-[(4-fluorophenyl)methylamino]-n-[4-[2-(1-methylpiperidin-4-yl)propan-2-yl]phenyl]benzamide Chemical compound C1CN(C)CCC1C(C)(C)C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1NCC1=CC=C(F)C=C1 OIPPARMLEWQGSK-UHFFFAOYSA-N 0.000 claims 1
- IKDAWKWPRPYNJA-UHFFFAOYSA-N 2-[1-(2-aminopyrimidin-4-yl)ethylamino]-n-(4,4-dimethyl-2,3-dihydro-1h-isoquinolin-7-yl)benzamide Chemical compound C=1C=CC=C(C(=O)NC=2C=C3C(C(CNC3)(C)C)=CC=2)C=1NC(C)C1=CC=NC(N)=N1 IKDAWKWPRPYNJA-UHFFFAOYSA-N 0.000 claims 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- COZSLNKBURQTJX-UHFFFAOYSA-N n-(1-acetyl-3,3-dimethyl-2h-indol-6-yl)-2-(quinolin-4-ylmethylamino)benzamide Chemical compound C1=CC=C2C(CNC3=CC=CC=C3C(=O)NC3=CC=C4C(C)(C)CN(C4=C3)C(=O)C)=CC=NC2=C1 COZSLNKBURQTJX-UHFFFAOYSA-N 0.000 claims 1
- IKTFEBNTUYTPCK-UHFFFAOYSA-N n-(1-ethyl-3,3-dimethyl-2h-indol-6-yl)-2-(pyridin-4-ylmethylamino)benzamide Chemical compound C1=C2N(CC)CC(C)(C)C2=CC=C1NC(=O)C1=CC=CC=C1NCC1=CC=NC=C1 IKTFEBNTUYTPCK-UHFFFAOYSA-N 0.000 claims 1
- YYVHACOWHFZZJT-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(quinolin-4-ylmethylamino)benzamide Chemical compound C1=CC=C2C(CNC3=CC=CC=C3C(=O)NC=3C=C4NCC(C4=CC=3)(C)C)=CC=NC2=C1 YYVHACOWHFZZJT-UHFFFAOYSA-N 0.000 claims 1
- QLFQMDKFOJZHBK-UHFFFAOYSA-N n-(4,4-dimethyl-2,3-dihydro-1h-isoquinolin-7-yl)-2-(pyridazin-4-ylmethylamino)benzamide Chemical compound C=1C=C2C(C)(C)CNCC2=CC=1NC(=O)C1=CC=CC=C1NCC1=CC=NN=C1 QLFQMDKFOJZHBK-UHFFFAOYSA-N 0.000 claims 1
- JQVREGRYMBTPRO-UHFFFAOYSA-N n-(4,4-dimethyl-2,3-dihydro-1h-isoquinolin-7-yl)-2-[(2-methoxypyridin-4-yl)methylamino]benzamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=CC=2)C(=O)NC=2C=C3C(C(CNC3)(C)C)=CC=2)=C1 JQVREGRYMBTPRO-UHFFFAOYSA-N 0.000 claims 1
- FTNKCGULGWHQPV-UHFFFAOYSA-N n-(4,4-dimethyl-2,3-dihydro-1h-isoquinolin-7-yl)-2-[(4-fluorophenyl)methylamino]benzamide Chemical compound C=1C=C2C(C)(C)CNCC2=CC=1NC(=O)C1=CC=CC=C1NCC1=CC=C(F)C=C1 FTNKCGULGWHQPV-UHFFFAOYSA-N 0.000 claims 1
- GUIOOGNPPDHMRU-UHFFFAOYSA-N n-(4,4-dimethyl-2,3-dihydro-1h-isoquinolin-7-yl)-2-[1-[2-(methylamino)pyrimidin-4-yl]ethylamino]benzamide Chemical compound CNC1=NC=CC(C(C)NC=2C(=CC=CC=2)C(=O)NC=2C=C3C(C(CNC3)(C)C)=CC=2)=N1 GUIOOGNPPDHMRU-UHFFFAOYSA-N 0.000 claims 1
- GUIOOGNPPDHMRU-MRXNPFEDSA-N n-(4,4-dimethyl-2,3-dihydro-1h-isoquinolin-7-yl)-2-[[(1r)-1-[2-(methylamino)pyrimidin-4-yl]ethyl]amino]benzamide Chemical compound CNC1=NC=CC([C@@H](C)NC=2C(=CC=CC=2)C(=O)NC=2C=C3C(C(CNC3)(C)C)=CC=2)=N1 GUIOOGNPPDHMRU-MRXNPFEDSA-N 0.000 claims 1
- SKHDQKQGFCSJDS-UHFFFAOYSA-N n-(4,4-dimethyl-2,3-dihydro-1h-isoquinolin-7-yl)-2-fluoro-6-[(2-methoxypyridin-4-yl)methylamino]benzamide Chemical compound C1=NC(OC)=CC(CNC=2C(=C(F)C=CC=2)C(=O)NC=2C=C3C(C(CNC3)(C)C)=CC=2)=C1 SKHDQKQGFCSJDS-UHFFFAOYSA-N 0.000 claims 1
- YAWXEPJVBFFVAI-UHFFFAOYSA-N n-(4,4-dimethyl-2,3-dihydro-1h-isoquinolin-7-yl)-3-fluoro-2-[(4-fluorophenyl)methylamino]benzamide Chemical compound C=1C=C2C(C)(C)CNCC2=CC=1NC(=O)C1=CC=CC(F)=C1NCC1=CC=C(F)C=C1 YAWXEPJVBFFVAI-UHFFFAOYSA-N 0.000 claims 1
- SHNBMTHPUCMPQC-UHFFFAOYSA-N n-(4,4-dimethyl-2,3-dihydro-1h-isoquinolin-7-yl)-4-fluoro-2-[(2-methoxypyridin-4-yl)methylamino]benzamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC=C(F)C=2)C(=O)NC=2C=C3C(C(CNC3)(C)C)=CC=2)=C1 SHNBMTHPUCMPQC-UHFFFAOYSA-N 0.000 claims 1
- FBSYURCCDOMSHX-UHFFFAOYSA-N n-(4,4-dimethyl-2,3-dihydro-1h-isoquinolin-7-yl)-5-fluoro-2-[(2-methoxypyridin-4-yl)methylamino]benzamide Chemical compound C1=NC(OC)=CC(CNC=2C(=CC(F)=CC=2)C(=O)NC=2C=C3C(C(CNC3)(C)C)=CC=2)=C1 FBSYURCCDOMSHX-UHFFFAOYSA-N 0.000 claims 1
- JQUISUUSKKADNO-UHFFFAOYSA-N n-(4,4-dimethyl-2,3-dihydro-1h-isoquinolin-7-yl)-6-fluoro-6-[(4-fluorophenyl)methylamino]cyclohexa-2,4-diene-1-carboxamide Chemical compound C=1C=C2C(C)(C)CNCC2=CC=1NC(=O)C1C=CC=CC1(F)NCC1=CC=C(F)C=C1 JQUISUUSKKADNO-UHFFFAOYSA-N 0.000 claims 1
- YHNUIHYDPTVZRY-UHFFFAOYSA-N n-(4,4-dimethyl-2,3-dihydro-1h-quinolin-7-yl)-2-(1h-pyrrolo[2,3-b]pyridin-3-ylmethylamino)benzamide Chemical compound C1=CC=C2C(CNC3=CC=CC=C3C(=O)NC=3C=C4NCCC(C4=CC=3)(C)C)=CNC2=N1 YHNUIHYDPTVZRY-UHFFFAOYSA-N 0.000 claims 1
- YTITUUIWIKQKDQ-UHFFFAOYSA-N n-(4-tert-butylphenyl)-2-(isoquinolin-7-ylamino)benzamide Chemical compound C1=CC(C(C)(C)C)=CC=C1NC(=O)C1=CC=CC=C1NC1=CC=C(C=CN=C2)C2=C1 YTITUUIWIKQKDQ-UHFFFAOYSA-N 0.000 claims 1
- MXMQURVEDWCCER-UHFFFAOYSA-N n-[4-[2-(1-methylpiperidin-4-yl)propan-2-yl]phenyl]-2-(pyridin-4-ylmethylamino)benzamide Chemical compound C1CN(C)CCC1C(C)(C)C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1NCC1=CC=NC=C1 MXMQURVEDWCCER-UHFFFAOYSA-N 0.000 claims 1
- HAZZWCMIYVZRGW-UHFFFAOYSA-N n-[4-[2-(1-methylpiperidin-4-yl)propan-2-yl]phenyl]-2-(quinolin-4-ylmethylamino)benzamide Chemical compound C1CN(C)CCC1C(C)(C)C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1NCC1=CC=NC2=CC=CC=C12 HAZZWCMIYVZRGW-UHFFFAOYSA-N 0.000 claims 1
- 125000005246 nonafluorobutyl group Chemical group FC(F)(F)C(F)(F)C(F)(F)C(F)(F)* 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39514402P | 2002-07-09 | 2002-07-09 | |
| US10/615,809 US7307088B2 (en) | 2002-07-09 | 2003-07-08 | Substituted anthranilic amide derivatives and methods of use |
| PCT/US2003/021601 WO2004005279A2 (en) | 2002-07-09 | 2003-07-09 | Substituted anthranilic amide derivatives and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006502112A JP2006502112A (ja) | 2006-01-19 |
| JP2006502112A5 true JP2006502112A5 (https=) | 2006-08-24 |
Family
ID=30118477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004520114A Pending JP2006502112A (ja) | 2002-07-09 | 2003-07-09 | 置換アントラニルアミド誘導体および使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7307088B2 (https=) |
| EP (1) | EP1519921A2 (https=) |
| JP (1) | JP2006502112A (https=) |
| AU (1) | AU2003256481B2 (https=) |
| CA (1) | CA2489166A1 (https=) |
| MX (1) | MXPA05000120A (https=) |
| PL (1) | PL375586A1 (https=) |
| WO (1) | WO2004005279A2 (https=) |
Families Citing this family (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10023484A1 (de) * | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylamide und deren Verwendung als Arzneimittel |
| US7615565B2 (en) * | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
| US7202260B2 (en) * | 2003-06-13 | 2007-04-10 | Schering Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones |
| KR101254371B1 (ko) | 2003-07-18 | 2013-05-02 | 암젠 프레몬트 인코포레이티드 | 간세포 성장인자에 결합하는 분리된 항체 |
| US20050130986A1 (en) * | 2003-11-21 | 2005-06-16 | Eklund Kari K. | Treatment of spondylarthropathies |
| US7507748B2 (en) | 2004-07-22 | 2009-03-24 | Amgen Inc. | Substituted aryl-amine derivatives and methods of use |
| EP1655295A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| EP1657241A1 (en) * | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| US7906533B2 (en) * | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| MX2007006230A (es) | 2004-11-30 | 2007-07-25 | Amgen Inc | Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer. |
| JP4834441B2 (ja) * | 2005-03-31 | 2011-12-14 | 参天製薬株式会社 | ピリミジニルアルキルチオ基を有する新規環式化合物 |
| ES2548729T3 (es) | 2005-03-31 | 2015-10-20 | Santen Pharmaceutical Co., Ltd. | Nuevo compuesto cíclico que tiene grupo pirimidinilalquiltio |
| US8247556B2 (en) * | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
| BRPI0619208A2 (pt) | 2005-11-30 | 2011-09-20 | Astellas Pharma Inc | derivado de 2-aminobenzamida c07d 307/14 c07d 307/22 c07d 309/14 c07d 319/12 c07d 401/12 c07d 405/12 c07d 413/12 c07d 417/12 |
| US20080108664A1 (en) | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
| AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| ATE489380T1 (de) | 2006-02-10 | 2010-12-15 | Amgen Inc | Hydratformen von amg706 |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| EP2125781A2 (en) | 2006-12-20 | 2009-12-02 | Amgen Inc. | Substituted heterocycles and methods of use |
| AU2008205252B2 (en) | 2007-01-09 | 2013-02-21 | Amgen Inc. | Bis-aryl amide derivatives useful for the treatment of cancer |
| AU2008219166B2 (en) | 2007-02-16 | 2013-05-16 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors |
| ES2650224T3 (es) | 2007-08-21 | 2018-01-17 | Amgen, Inc. | Proteínas de unión al antígeno C-FMS humano |
| US8586571B2 (en) | 2007-10-18 | 2013-11-19 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US9126935B2 (en) | 2008-08-14 | 2015-09-08 | Amgen Inc. | Aurora kinase modulators and methods of use |
| MX2011006564A (es) * | 2008-12-19 | 2011-09-26 | Amgen Inc | Procedimiento mejorado para la preparacion de 1-acetil-6-amino-3,3-dimetil-2,3-dihidroindol. |
| MX2011010058A (es) | 2009-03-25 | 2011-10-11 | Abbott Lab | Compuestos antivirales y usos de los mismos. |
| CA2758895A1 (en) | 2009-04-16 | 2010-10-21 | Takeda Pharmaceutical Company Limited | Derivatives of n-acyl-n'-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes |
| WO2011161217A2 (en) | 2010-06-23 | 2011-12-29 | Palacký University in Olomouc | Targeting of vegfr2 |
| CN103703000B (zh) | 2011-03-23 | 2015-11-25 | 安姆根有限公司 | Cdk4/6和flt3的稠合三环双重抑制剂 |
| US9745288B2 (en) | 2011-08-16 | 2017-08-29 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| WO2014036022A1 (en) | 2012-08-29 | 2014-03-06 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
| AU2015326506B2 (en) * | 2014-10-03 | 2021-02-25 | Divya MAHESHWARI | Novel anthranilic acid derivatives |
| US11083755B2 (en) | 2015-01-08 | 2021-08-10 | The Board Of Trustees Of The Leland Stanford Junior University | Factors and cells that provide for induction of bone, bone marrow, and cartilage |
| WO2016144702A1 (en) | 2015-03-06 | 2016-09-15 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| JP6697809B2 (ja) | 2015-03-06 | 2020-05-27 | ファーマケア，インク． | フッ素化リシルオキシダーゼ様２阻害剤とその使用 |
| WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
| KR102587178B1 (ko) | 2016-09-07 | 2023-10-06 | 파마케아, 인크. | 리실 옥시다아제-유사 2 억제제의 결정질 형태 및 제조 방법 |
| KR102615565B1 (ko) | 2016-09-07 | 2023-12-18 | 파마케아, 인크. | 리실 옥시다제 유사 2 억제제의 용도 |
| WO2018119183A2 (en) | 2016-12-22 | 2018-06-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| AR110963A1 (es) * | 2017-02-07 | 2019-05-22 | Dae Woong Pharma | Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende |
| EA201992781A1 (ru) | 2017-05-22 | 2020-04-01 | Эмджен Инк. | Ингибиторы g12c kras и способы их применения |
| WO2019006025A1 (en) * | 2017-06-29 | 2019-01-03 | The Regents Of The University Of California | AROMATIC 2-NITROSULFONYL FLUORIDE ANTIBIOTICS AND METHODS OF USE |
| CN109422655B (zh) * | 2017-08-24 | 2021-10-29 | 中国石油化工股份有限公司 | 一种苯酚直接氨化制苯胺的方法 |
| MA50077A (fr) | 2017-09-08 | 2020-07-15 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| ES2995514T3 (en) | 2018-05-04 | 2025-02-10 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
| WO2019213516A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| EP3790886B1 (en) | 2018-05-10 | 2024-06-26 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
| ES2938987T3 (es) | 2018-06-01 | 2023-04-18 | Amgen Inc | Inhibidores de KRAS G12c y métodos de uso de los mismos |
| US20190375749A1 (en) | 2018-06-11 | 2019-12-12 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| ES3060664T3 (en) | 2018-06-12 | 2026-03-27 | Amgen Inc | Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法 |
| US11053226B2 (en) | 2018-11-19 | 2021-07-06 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| JP7676308B2 (ja) | 2018-12-20 | 2025-05-14 | アムジエン・インコーポレーテツド | Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド |
| EP3898616B1 (en) | 2018-12-20 | 2024-10-02 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| TWI844602B (zh) | 2018-12-20 | 2024-06-11 | 美商安進公司 | Kif18a抑制劑 |
| WO2020132651A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
| WO2020180768A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| CN113727758A (zh) | 2019-03-01 | 2021-11-30 | 锐新医药公司 | 双环杂环基化合物及其用途 |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| NZ782284A (en) | 2019-05-21 | 2024-11-29 | Amgen Inc | Solid state forms |
| US12540129B2 (en) | 2019-08-02 | 2026-02-03 | Amgen Inc. | KIF18A inhibitors |
| AU2020326627B2 (en) | 2019-08-02 | 2026-01-29 | Amgen Inc. | KIF18A inhibitors |
| EP4007756B1 (en) | 2019-08-02 | 2025-12-24 | Amgen Inc. | Kif18a inhibitors |
| WO2021026099A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| EP4684786A3 (en) | 2019-10-24 | 2026-04-08 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| CN120699039A (zh) | 2019-11-04 | 2025-09-26 | 锐新医药公司 | Ras抑制剂 |
| TW202128688A (zh) | 2019-11-08 | 2021-08-01 | 美商銳新醫藥公司 | 雙環雜芳基化合物及其用途 |
| WO2021097207A1 (en) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
| JP2023501528A (ja) | 2019-11-14 | 2023-01-18 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の改善された合成 |
| EP4065231A1 (en) | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| CN114929279A (zh) | 2020-01-07 | 2022-08-19 | 锐新医药公司 | Shp2抑制剂给药和治疗癌症的方法 |
| IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
| MX2023002248A (es) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. |
| MX2023003060A (es) | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
| WO2022063115A1 (zh) * | 2020-09-24 | 2022-03-31 | 贝达药业股份有限公司 | 双环化合物及其应用 |
| US20240051956A1 (en) | 2020-12-22 | 2024-02-15 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
| CA3217393A1 (en) | 2021-05-05 | 2022-11-10 | Elena S. Koltun | Ras inhibitors |
| AU2022268962A1 (en) | 2021-05-05 | 2023-12-14 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| TW202340214A (zh) | 2021-12-17 | 2023-10-16 | 美商健臻公司 | 做為shp2抑制劑之吡唑并吡𠯤化合物 |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| WO2023172858A1 (en) | 2022-03-07 | 2023-09-14 | Amgen Inc. | A process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| AU2023358792A1 (en) | 2022-10-14 | 2025-04-17 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| KR20260005904A (ko) | 2023-04-07 | 2026-01-12 | 레볼루션 메디슨즈, 인크. | 매크로사이클릭 ras 억제제 |
| CN121263418A (zh) | 2023-04-07 | 2026-01-02 | 锐新医药公司 | 大环ras抑制剂 |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| KR20250172857A (ko) | 2023-04-14 | 2025-12-09 | 레볼루션 메디슨즈, 인크. | Ras 억제제의 결정형 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202542151A (zh) | 2023-12-22 | 2025-11-01 | 美商銳格醫藥有限公司 | Ｓｏｓ１抑制劑及其用途 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH438343A (de) | 1962-11-08 | 1967-06-30 | Thomae Gmbh Dr K | Verfahren zur Herstellung von 5,6-Dihydro-6-oxo-11H-pyrido (2,3-b) (1,4)-benzodiazepinen |
| US3226394A (en) | 1964-06-16 | 1965-12-28 | Shulton Inc | Pyridylethylated anthranilamides and derivatives thereof |
| US3822277A (en) | 1967-11-13 | 1974-07-02 | C Dufour | Certain pyridyl cyclopropylamides |
| US3452019A (en) | 1967-11-16 | 1969-06-24 | Wallace & Tiernan Inc | 1-phenylalkyl-tetrahydro-halo-sulfamyl-quinazolinone |
| US3557111A (en) | 1968-03-29 | 1971-01-19 | Bola Vithal Shetty | N and n,n-alkyl,acyl and arylsulfamyl-tetrahydroquinazolinones |
| US3567746A (en) | 1968-07-10 | 1971-03-02 | Pennwalt Corp | N-aryl benzamides |
| BE794226A (fr) | 1972-01-21 | 1973-07-18 | Synthelabo | Derives de la quinoleine, leur preparation et les medicaments qui en contiennent |
| GB1474296A (en) | 1975-01-23 | 1977-05-18 | Wyeth John & Brother Ltd | 4-aminoquinoline derivatives |
| GB1573186A (en) | 1977-09-14 | 1980-08-20 | Wyeth John & Brother Ltd | 4-aminoquinoline derivatives |
| DE2934543A1 (de) | 1979-08-27 | 1981-04-02 | Basf Ag, 6700 Ludwigshafen | Substituierte n-benzoylanthranilsaeurederivate und deren anydroverbindungen, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
| JPH0233030B2 (ja) | 1982-01-18 | 1990-07-25 | Mitsui Toatsu Chemicals | Surufuamoiruansokukosanjudotaioyobisoreojukoseibuntoshitefukumuchiryoyososeibutsu |
| FR2540870A1 (fr) | 1983-02-15 | 1984-08-17 | Provesan Sa | Nouveaux derives de betaines n-iminopyridinium, leur preparation et leur application en tant que medicaments |
| SU1156362A1 (ru) | 1983-02-17 | 1991-07-30 | Пермский государственный фармацевтический институт | Ариламиды П-(2 @ ,4 @ )- или (3 @ ,4 @ )-диметоксибензилантраниловых кислот как промежуточные вещества дл синтеза биологически активных перхлоратов 1-[(2 @ ,4 @ ) или (3 @ ,4 @ )-диметоксибензил]-2-метил-3-арил-4-(3Н)-хиназолинони |
| DE3305755A1 (de) | 1983-02-19 | 1984-08-23 | Gödecke AG, 1000 Berlin | N-phenyl-benzamid-derivate, verfahren zu deren herstellung und deren verwendung bei der bekaempfung von erkranungen des immunsystems |
| ES2058656T3 (es) | 1989-04-20 | 1994-11-01 | Boehringer Ingelheim Pharma | 5,11-dihidro-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepin-6-onas y su uso en la prevencion o tratamiento del sida. |
| CA2019812C (en) | 1989-06-28 | 2000-11-21 | Gunther Schmidt (Deceased) | Novel 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-ones and their use in the prevention or treatment of aids |
| CA2030056C (en) | 1989-11-17 | 1995-10-17 | Karl D. Hargrave | 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of hiv infection |
| US5571912A (en) | 1990-10-19 | 1996-11-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the preparation of 5,11-dihydro-6h-dipyrido [3,2-b:2',3'-e][1,4]diazepines |
| EP1195372A1 (en) | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-heterocyclic substituted benzamide derivatives with antihypertensive activity |
| US5559135A (en) | 1994-09-14 | 1996-09-24 | Merck & Co., Inc. | Endothelin antagonists bearing pyridyl amides |
| US5532358A (en) | 1994-10-12 | 1996-07-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for preparing alkyl-5,11-dihydro-6h-dipyrido[3,2-B:2',3'-E] [1,4] diazepin-6-ones |
| GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
| US5770613A (en) | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
| US5663357A (en) | 1995-11-22 | 1997-09-02 | Allergan | Substituted heteroarylamides having retinoid-like biological activity |
| US6008234A (en) | 1996-09-12 | 1999-12-28 | Berlex Laboratories, Inc. | Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants |
| AUPO395396A0 (en) | 1996-12-02 | 1997-01-02 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
| TW523506B (en) | 1996-12-18 | 2003-03-11 | Ono Pharmaceutical Co | Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients |
| NZ337698A (en) | 1997-04-04 | 2001-07-27 | Pfizer Prod Inc | Nicotinamide derivatives for selective inhibition of phosphodiesterase type 4 (PDE4) and the production of tumour necrosis factor (TNF) useful for the treatment of respiratory, rheumatoid and allergic diseases |
| US5919970A (en) | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
| IL133625A0 (en) | 1997-06-26 | 2001-04-30 | Lilly Co Eli | Antithrombotic agents |
| IL133627A0 (en) | 1997-06-26 | 2001-04-30 | Lilly Co Eli | Antithrombotic agents |
| US6372759B1 (en) | 1997-06-26 | 2002-04-16 | Eli Lilly And Company | Antithrombotic agents |
| EP1014962A4 (en) | 1997-06-26 | 2007-06-27 | Lilly Co Eli | ANTITHROMBOTIC AGENTS |
| US6140351A (en) | 1997-12-19 | 2000-10-31 | Berlex Laboratories, Inc. | Ortho-anthranilamide derivatives as anti-coagulants |
| EP1040108B1 (en) | 1997-12-19 | 2004-02-25 | Schering Aktiengesellschaft | Ortho-anthranilamide derivatives as anti-coagulants |
| US6271237B1 (en) | 1997-12-22 | 2001-08-07 | Dupont Pharmaceuticals Company | Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors |
| CA2332957A1 (en) | 1998-06-05 | 1999-12-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents |
| CN1332943C (zh) | 1998-07-08 | 2007-08-22 | 萨诺费－阿文蒂斯德国有限公司 | 硫取代的磺酰基氨基羧酸n－芳基酰胺,其制备方法、用途以及含有该化合物的药物制剂 |
| US6331640B1 (en) * | 1998-10-13 | 2001-12-18 | Hoffmann-La Roche Inc. | Diaminopropionic acid derivatives |
| GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
| UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| EP1140905B1 (en) | 1998-12-23 | 2003-05-14 | Eli Lilly And Company | Heteroaromatic amides as inhibitor of factor xa |
| AU2054700A (en) | 1998-12-23 | 2000-07-31 | Eli Lilly And Company | Antithrombotic amides |
| ATE272633T1 (de) | 1998-12-23 | 2004-08-15 | Lilly Co Eli | Aromatische amiden |
| JP2000256358A (ja) | 1999-03-10 | 2000-09-19 | Yamanouchi Pharmaceut Co Ltd | ピラゾール誘導体 |
| DE19941540C2 (de) | 1999-09-01 | 2002-08-29 | Aventis Pharma Gmbh | Sulfonylcarboxamide zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Hyperlipidämie |
| GB9924862D0 (en) | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
| AUPQ365299A0 (en) | 1999-10-25 | 1999-11-18 | Fujisawa Pharmaceutical Co., Ltd. | Anthranilic acid derivatives |
| AU2001231143A1 (en) | 2000-01-27 | 2001-08-07 | Cytovia, Inc. | Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| GB0001930D0 (en) | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
| AU2001250783A1 (en) | 2000-02-29 | 2001-09-12 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| DE10021246A1 (de) | 2000-04-25 | 2001-10-31 | Schering Ag | Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel |
| DE10023486C1 (de) * | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
| DE10023492A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel |
| DE10023485A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylalkyl- und -cycloalkylamide und deren Verwendung als Arzneimittel |
| DE10023484A1 (de) | 2000-05-09 | 2001-11-22 | Schering Ag | Anthranylamide und deren Verwendung als Arzneimittel |
| US6934248B1 (en) | 2000-07-20 | 2005-08-23 | Nortel Networks Limited | Apparatus and method for optical communication protection |
| DE10060809A1 (de) | 2000-12-07 | 2002-06-20 | Aventis Pharma Gmbh | Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker |
| EP1394154A4 (en) | 2001-03-23 | 2005-05-18 | Takeda Pharmaceutical | FIVE-GLASS HETEROCYCLIC ALKANIC ACID DERIVATIVE |
| US7312235B2 (en) | 2001-03-30 | 2007-12-25 | Millennium Pharmaceuticals, Inc. | Benzamide inhibitors of factor Xa |
| MXPA03010099A (es) * | 2001-05-08 | 2004-03-10 | Schering Ag | Amidas de antranilamida-piridina selectivas como inhibidores de vegfr-2 y vegfr-3. |
| DE10125295A1 (de) | 2001-05-15 | 2002-11-21 | Schering Ag | Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel (II) |
| JP4343681B2 (ja) * | 2001-05-08 | 2009-10-14 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | シアノアントラニルアミド誘導体およびそれらの薬剤としての使用 |
| US7459470B2 (en) | 2001-05-08 | 2008-12-02 | Schering Ag | N-oxide anthranylamide derivatives and their use as medicaments |
| GB0126901D0 (en) * | 2001-11-08 | 2002-01-02 | Novartis Ag | Organic compounds |
| GB0126902D0 (en) * | 2001-11-08 | 2002-01-02 | Novartis Ag | Organic compounds |
| GB0203193D0 (en) | 2002-02-11 | 2002-03-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| KR100698982B1 (ko) | 2002-02-11 | 2007-03-26 | 화이자 인코포레이티드 | Ｐｄｅ4 억제제로서 유용한 니코틴아미드 유도체 |
| US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| US7517894B2 (en) | 2002-07-31 | 2009-04-14 | Bayer Schering Pharma Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
-
2003
- 2003-07-08 US US10/615,809 patent/US7307088B2/en not_active Expired - Lifetime
- 2003-07-09 MX MXPA05000120A patent/MXPA05000120A/es not_active Application Discontinuation
- 2003-07-09 EP EP03763451A patent/EP1519921A2/en not_active Withdrawn
- 2003-07-09 AU AU2003256481A patent/AU2003256481B2/en not_active Ceased
- 2003-07-09 PL PL03375586A patent/PL375586A1/xx unknown
- 2003-07-09 JP JP2004520114A patent/JP2006502112A/ja active Pending
- 2003-07-09 CA CA002489166A patent/CA2489166A1/en not_active Abandoned
- 2003-07-09 WO PCT/US2003/021601 patent/WO2004005279A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006502112A5 (https=) | ||
| JP2004527499A5 (https=) | ||
| JP2004531473A5 (https=) | ||
| JP2004531484A5 (https=) | ||
| JP2006520805A5 (https=) | ||
| JP2007504148A5 (https=) | ||
| CA2434178A1 (en) | Substituted amine derivatives and methods of use | |
| CN100502863C (zh) | 2,4,5-三取代噻唑衍生物和它们的抗炎活性 | |
| JP2007503450A5 (https=) | ||
| JP2020512343A5 (https=) | ||
| CA2717948C (en) | 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes | |
| CA2571627A1 (en) | Substituted aryl-amine derivatives and methods of use | |
| JP2008525498A5 (https=) | ||
| JP2009515814A5 (https=) | ||
| JP2019537571A5 (https=) | ||
| RU2672910C2 (ru) | Гетероароматические соединения как модуляторы фосфоинозитид-3-киназы | |
| JP2008525502A5 (https=) | ||
| TW201718508A (zh) | 作為激酶抑制劑之雜環醯胺 | |
| JP2010514721A5 (https=) | ||
| RU2011114487A (ru) | Гетероциклические соединения как ингибиторы протеинкиназы | |
| RU2006112046A (ru) | Производные пиррола с антибактериальным действием | |
| JP2012532931A5 (https=) | ||
| AU2009298006A1 (en) | Pyrazolo pyridine derivatives as NADPH Oxidase inhibitors | |
| UA77167C2 (uk) | Похідні заміщених алкіламінів та їх застосування | |
| JP2010521522A5 (https=) |